시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 세균성 이질 예방 시장 보고서(2025년)
Shigella Diarrhoea Prophylaxis Global Market Report 2025
상품코드 : 1769747
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,310,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,121,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,932,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

세균성 이질 예방 시장 규모는 향후 몇 년간 강력한 성장이 전망될 예정입니다. 예방조치를 필요로 하는 감염증의 재발 위험, 위생을 촉진하는 공중위생 이니셔티브의 고조, 설사 예방 프로그램의 세계의 우선순위화, 지역 보건 교육의 광범위한 실시, 백신 접종의 일반 대중의 수용과 인지도의 향상이 원동력이 되고 있습니다. 예측 기간에 있어서의 주요 동향으로서는 백신 연구 개발의 진전, 이질균을 표적으로 한 혁신적인 경구 백신의 도입, 백신 전달 방법의 발전, 광역 예방 치료법의 창출, 예방적 개입을 더 잘 지시하기 위한 신속한 진단 도구의 가용성 등이 있습니다.

위생과 공중위생에 대한 의식의 고조가 향후 몇 년간의 세균성 이질 예방 시장의 확대를 촉진할 것으로 예측됩니다. 위생 인식의 증가는 건강 위험에 대한 더 나은 이해와 더 많은 사람들이 청결이 전염병 확산을 막는 데 중요한 역할을 한다는 인식으로 인해 촉진됩니다. 예를 들어 2024년 3월 세계보건기구(WHO)는 세계 인구의 57%에 해당하는 46억명이 안전하게 관리된 위생 서비스를 이용할 수 있다고 보고했습니다. 이 중 33%인 27억 명은 하수 처리장과 연결된 개인 위생 시설을 이용했으며, 21%에 해당하는 17억명이, 배설물을 그 자리에서 안전하게 처리하는 화장실이나 변소를 이용하고 있었습니다.

세균성 이질 예방 시장의 주요 기업은 면역 반응을 향상시키는 4가 생체접합 이질 백신과 같은 첨단 솔루션의 개발에 주력하고 있습니다. 4가지 주요 이질균 혈청형으로부터 보호하기 위해 설계되었습니다. 4V2(S4V2)의 제2상 유아 안전성 및 면역원성 시험에 있어서, 최초의 참가자가 백신 접종을 받았다고 발표했습니다. 세균성 이질 질환의 주요 원인인 이질균에 대한 백신 개발에 있어서의 주요 이정표가 됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

SHW
영문 목차

영문목차

Shigella diarrhoea prophylaxis refers to preventive strategies aimed at reducing the risk of infection caused by Shigella bacteria, which are responsible for acute diarrhoeal illness. This type of prophylaxis targets breaking the transmission cycle of the pathogen by enhancing sanitation, promoting personal hygiene, ensuring safe food and water handling, and implementing public health interventions.

The primary forms of shigella diarrhoea prophylaxis include vaccination, antibiotic prophylaxis, public health initiatives, and hygiene education. Vaccination involves administering a vaccine to activate the immune system against specific pathogens. Vaccines can be given orally, parenterally, or via other routes and are utilized by various end-users including healthcare facilities, travel clinics, pharmacies, and government health programs.

The shigella diarrhoea prophylaxis market research report is one of a series of new reports from The Business Research Company that provides shigella diarrhoea prophylaxis market statistics, including the shigella diarrhoea prophylaxis industry global market size, regional shares, competitors with the shigella diarrhoea prophylaxis market share, detailed shigella diarrhoea prophylaxis market segments, market trends, and opportunities, and any further data you may need to thrive in the shigella diarrhoea prophylaxis industry. This shigella diarrhoea prophylaxis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The shigella diarrhoea prophylaxis market size has grown strongly in recent years. It will grow from $1.95 billion in 2024 to $2.12 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. This historical growth can be linked to the rising incidence of shigella infections worldwide, increased awareness regarding food and waterborne illnesses, frequent outbreaks in refugee camps and densely populated urban settings, escalating antibiotic resistance in shigella strains, and a growing number of cases in children under five years old.

The shigella diarrhoea prophylaxis market size is expected to see strong growth in the next few years. It will grow to $2.88 billion in 2029 at a compound annual growth rate (CAGR) of 8%. The anticipated expansion is driven by the risk of recurrent infections requiring preventive actions, the rise in public health initiatives promoting hygiene, the global prioritization of diarrhoea prevention programs, broader implementation of community health education, and increasing public acceptance and awareness of vaccination. Key trends over the forecast period include progress in vaccine research and development, introduction of innovative oral vaccines targeting shigella, advancements in vaccine delivery methods, creation of broad-spectrum prophylactic treatments, and the availability of rapid diagnostic tools to better direct prophylactic interventions.

The growing awareness of hygiene and sanitation is anticipated to drive the expansion of the shigella diarrhoea prophylaxis market in the coming years. Hygiene and sanitation encompass actions and environmental conditions that promote health and limit disease transmission through cleanliness and proper waste management. This increase in hygiene awareness is fueled by a better understanding of health risks, with more individuals recognizing the critical role cleanliness plays in preventing infectious disease spread. Such awareness supports shigella diarrhoea prophylaxis by reducing person-to-person transmission, as people who practice proper handwashing and waste disposal significantly decrease the chances of spreading the bacteria within communities. For example, in March 2024, the World Health Organization reported that 57% of the global population, or 4.6 billion people, had access to safely managed sanitation services. Of these, 33%, or 2.7 billion people, used private sanitation facilities connected to sewers where wastewater was treated, while 21%, or 1.7 billion people, used toilets or latrines that safely disposed of waste on-site. Thus, the rising awareness of hygiene and sanitation will boost growth in the shigella diarrhoea prophylaxis market.

Leading companies in the shigella diarrhoea prophylaxis market are concentrating on developing advanced solutions like tetravalent bioconjugate shigellosis vaccines to improve immune responses. These tetravalent bioconjugate vaccines are designed to protect against four major Shigella serotypes by linking bacterial polysaccharides to a carrier protein, enhancing the immune response. For instance, in November 2024, Valneva SE, a biotech company based in France, and LimmaTech Biologics AG, a Switzerland-based clinical-stage biotech firm, announced that the first participant had been vaccinated in a Phase 2 infant safety and immunogenicity study of Shigella4V2 (S4V2). This vaccine candidate is currently the most clinically advanced tetravalent bioconjugate vaccine targeting shigellosis globally. This represents a key milestone in efforts to develop a vaccine against Shigella, a leading cause of severe diarrheal disease in children. The S4V2 vaccine will be tested for safety and preliminary efficacy in approximately 120 healthy adults aged 18 to 50 who have not previously been exposed to Shigella at three U.S. locations.

In August 2024, Valneva SE, a specialty vaccine company based in France, partnered with LimmaTech to accelerate the development of the advanced tetravalent shigella vaccine candidate. This collaboration allows Valneva to advance a promising program that addresses a critical unmet medical need and highlights LimmaTech's expertise in vaccine development and their capability to rapidly accelerate program progress. LimmaTech is a Switzerland-based company focused on developing the tetravalent shigella vaccine candidate.

Major players in the shigella diarrhoea prophylaxis market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., GlaxoSmithKline plc, Viatris Inc., Chongqing Zhifei Biological Products Co. Ltd., Macleods Pharmaceuticals Limited, Alkem Laboratories Limited, Alembic Pharmaceuticals Limited, Vaxcyte Inc., Valneva SE, Sanaria Inc., Intravacc B.V., LimmaTech Biologics AG, Eveliqure Biotechnologies GmbH, Intralytix Inc., Immuron Limited, Biocidium Biopharmaceuticals Inc., Institut Pasteur, and Hetero Drugs Limited.

North America was the largest region in the shigella diarrhoea prophylaxis market in 2024. The regions covered in shigella diarrhoea prophylaxis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the shigella diarrhoea prophylaxis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The shigella diarrhoea prophylaxis market consists of revenues earned by entities by providing services such as water quality testing, educational campaigns, infection control consulting, and food safety services. The market value includes the value of related goods sold by the service provider or included within the service offering. The shigella diarrhoea prophylaxis market also includes sales of hand sanitizers, antibacterial soaps, disinfectants, and surface cleaner. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Shigella Diarrhoea Prophylaxis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on shigella diarrhoea prophylaxis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for shigella diarrhoea prophylaxis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The shigella diarrhoea prophylaxis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Shigella Diarrhoea Prophylaxis Market Characteristics

3. Shigella Diarrhoea Prophylaxis Market Trends And Strategies

4. Shigella Diarrhoea Prophylaxis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Shigella Diarrhoea Prophylaxis Growth Analysis And Strategic Analysis Framework

6. Shigella Diarrhoea Prophylaxis Market Segmentation

7. Shigella Diarrhoea Prophylaxis Market Regional And Country Analysis

8. Asia-Pacific Shigella Diarrhoea Prophylaxis Market

9. China Shigella Diarrhoea Prophylaxis Market

10. India Shigella Diarrhoea Prophylaxis Market

11. Japan Shigella Diarrhoea Prophylaxis Market

12. Australia Shigella Diarrhoea Prophylaxis Market

13. Indonesia Shigella Diarrhoea Prophylaxis Market

14. South Korea Shigella Diarrhoea Prophylaxis Market

15. Western Europe Shigella Diarrhoea Prophylaxis Market

16. UK Shigella Diarrhoea Prophylaxis Market

17. Germany Shigella Diarrhoea Prophylaxis Market

18. France Shigella Diarrhoea Prophylaxis Market

19. Italy Shigella Diarrhoea Prophylaxis Market

20. Spain Shigella Diarrhoea Prophylaxis Market

21. Eastern Europe Shigella Diarrhoea Prophylaxis Market

22. Russia Shigella Diarrhoea Prophylaxis Market

23. North America Shigella Diarrhoea Prophylaxis Market

24. USA Shigella Diarrhoea Prophylaxis Market

25. Canada Shigella Diarrhoea Prophylaxis Market

26. South America Shigella Diarrhoea Prophylaxis Market

27. Brazil Shigella Diarrhoea Prophylaxis Market

28. Middle East Shigella Diarrhoea Prophylaxis Market

29. Africa Shigella Diarrhoea Prophylaxis Market

30. Shigella Diarrhoea Prophylaxis Market Competitive Landscape And Company Profiles

31. Shigella Diarrhoea Prophylaxis Market Other Major And Innovative Companies

32. Global Shigella Diarrhoea Prophylaxis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Shigella Diarrhoea Prophylaxis Market

34. Recent Developments In The Shigella Diarrhoea Prophylaxis Market

35. Shigella Diarrhoea Prophylaxis Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기